Aschalew Nardos

Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia

Publications

  • Research Article   

    Author(s): Beyene Dereje57221* and Aschalew Nardos57223

    Background: Dopamine 2 receptor agonists, Bromocriptine and Cabergoline, were originally introduced for prolactinomas and pituitary tumors but have glucose-lowering effects. This paper studied the significance of their effects on lowering blood glucose level and conducted a comprehensive analysis to identify relevant clinical trials of dopamine 2 agonists on Glycated Hemoglobin (HbA1c) and Fasting Blood Sugar (FBS). Methods: We conducted a study using different databases; PubMed, Google Scholar, Cochrane Library, HINARI, Registers, and Citations until December 31, 2022 using the PRISMA 2020 statement, looking for studies relevant to clinical studies on FBS and HbA1c. Jadad score were used to assess the study quality. The study included studies with full abstracts, predefined garlic doses, clear interve.. Read More»
    DOI: 10.31858/0975-8453.14.4.286-295

    Abstract HTML PDF